[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566786":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":27,"studyPopulation":20,"armGroups":28,"interventions":35,"overallOfficials":41,"centralContacts":45,"locations":54,"responsibleParty":72,"collaborators":20,"id":74,"slug":20,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":20,"enrollmentInfo":83,"targetDuration":20,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":57,"whyStopped":20,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Institut Curie","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"EFS: Event Free Survival","Time from diagnosis to disease progression, recurrence or death (EFS: Event Free Survival). Radiomic features from the initial FAPI evaluation will be analyzed using univariable and multivariable survival models to detect and quantify statistical associations between feature values and EFS. A multivariable model will be proposed and will serve as basis for the estimation of screening sensitivity.","12 months",[14,17],{"measure":15,"description":16,"timeFrame":12},"Adverse Event during 68Ga-FAPI-46 PET\u002FCT exams","Description the safety profile of 68Ga-FAPI-46 PET\u002FCT exams",{"measure":18,"description":19,"timeFrame":12},"Evaluation of the tumor burden 68Ga-FAPI-46 PET\u002FCT versus 18F-FDG PET\u002FCT","Comparison of 68Ga-FAPI-46 PET\u002FCT and 18F-FDG PET\u002FCT (Comparison of the tumor burden using the total FAP expression tumor volume\u002FTFTV and the total metabolic tumor volume\u002FTMTV\\*, respectively)",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":20,"primaryPurpose":24,"observationalModel":20,"timePerspective":20,"maskingInfo":25},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":26,"maskingDescription":20,"whoMasked":20},"NONE","Development of imaging biomarkers derived from FAPI PET among patients with a newly-diagnosed resectable or locally advanced PDAC, in order (i) to detect a metastatic disease at inclusion and (ii) to detect disease recurrence after surgical resection with a higher sensitivity than the standard evaluation.\n\nProspective cohort involving repeated medical imaging with a new radiotracer (FAPI). Patients meeting inclusion criteria will be stratified according to the disease staging: resectable, borderline or locally advanced PDAC.\n\nAt inclusion after confirmed non-metastatic PDAC diagnosis, all patients will have:\n\nBaseline exams (V1) with 68Ga-FAPI-46 PET\u002FCT and 18F-FDG PET\u002FCT (within 1 month after inclusion in HoMING study) for all enrolled patients with resectable, borderline or locally advanced PDAC at inclusion.\n\nSecond pre-operative exams (V1b) with 68Ga-FAPI-46 PET\u002FCT and 18F-FDG PET\u002FCT exams only for patients who received neoadjuvant\u002Finduction treatment.\n\nPost-operative\u002FFollow-up exams (V2 to Vn) with 68Ga-FAPI-46 PET\u002FCT starting 2 months after surgery (with or without neoadjuvant\u002Finduction treatment) or following the neoadjuvant\u002Finduction treatment even if the patient is eventually not eligible for surgery (+\u002F-1 month), and then every 3 months (+\u002F-1 month).\n\nAll patients of this study must have been previously enrolled in the HoMING cohort (NCT 04363983, sponsor APHP). Endpoints and clinical characteristics, as well as results of other biological or imaging exams (MRI, spectral and conventional CT), will be shared with the HoMING cohort.\n\nThe follow-up ends as soon as conventional CT images show a disease progression\u002Frecurrence.\n\nInvestigators and patients will be blinded for the results of FAPI. Patients will be followed-up according to the care schedule with no modification of patient management. When disease progression\u002Frecurrence is diagnosed by conventional CT scan (gold standard), FAPI PET imaging at earlier time points (t -3 months, -6 months…) will be post-hoc reviewed to see whether small lesions could have been detected.",[29],{"label":30,"type":31,"description":32,"interventionNames":33},"Prospective cohort involving repeated medical imaging with a new radiotracer (68Ga-FAPI-46)","EXPERIMENTAL","All patients of this study must have been previously enrolled in the HoMING cohort (NCT 04363983, sponsor APHP).",[34],"Drug: 68Ga-FAPI-46 for PET \u002F CT scan",[36],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":20},"DRUG","68Ga-FAPI-46 for PET \u002F CT scan","Gallium 68-labeled fibroblast activation protein inhibitor (FAPI) used as radiotracer during PET imaging.",[30],[42],{"name":43,"affiliation":5,"role":44},"Nicolas Deleval","PRINCIPAL_INVESTIGATOR",[46,51],{"name":47,"role":48,"phone":49,"phoneExt":20,"email":50},"Marie-Emmanuelle LEGRIER","CONTACT","0033156245765","drci.promotion@curie.fr",{"name":52,"role":48,"phone":53,"phoneExt":20,"email":50},"Sandra NESPOULOUS","0033147111654",[55],{"facility":56,"status":57,"city":58,"state":20,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Institut Curie -site Saint-Cloud","RECRUITING","Saint-Cloud","92210","France","FR",{"type":63,"coordinates":64},"Point",[65,66],2.20289,48.84598,{"lat":66,"lon":65},[69,71],{"name":70,"role":48,"phone":20,"phoneExt":20,"email":20},"Nicolas Deleval, MD",{"name":70,"role":44,"phone":20,"phoneExt":20,"email":20},{"type":73,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100566786",false,"NCT06659705","Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)","Cutting Edge Imaging for Earlier Pancreatic Cancer Diagnosis: Evaluation of Positron Emission Tomography (PET) With the Fibroblast Activation Protein Inhibitor (FAPI)","INDIGO-FAPI","Inclusion Criteria:\n\n1. Cyto\u002Fhistologically proven PDAC\n2. Non-metastatic proven PDAC on recent (\\\u003C 1 month) CT-scan and MRI\n3. Concomitant enrollment in the HoMING prospective cohort (Sponsor: AP-HP, NCT04363983)\n4. Age \\> 18 years old\n5. Affiliation to a social security scheme\n6. Signed informed consent\n\nExclusion Criteria:\n\n1. Protected adults (guardianship, curatorship or safeguarding justice)\n2. Pregnant or breastfeeding woman\n3. Women of childbearing potential not using one highly effective method of contraception","ALL","18 Years",{"count":84,"type":85},35,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","Assessment of the relevance of a new medical imaging test, FAPI PET, which could detect progression or relapse earlier than other tests currently available. Ultimately, it could enable early forms of pancreatic cancer to be detected and used for screening.\n\nIn addition to the usual examinations prescribed, FAPI PET scans will be repeated at several points in the treatment process.\n\nAll study patients must first have been included in the Homing cohort (NCT 04363983, APHP promotion). Clinical characteristics, judgement criteria and results of biological or imaging examinations carried out as part of this cohort will be shared.\n\nPatient follow-up and participation in the study ends when conventional imaging (CT and MRI) shows disease progression, relapse or death.",[91],"Pancreatic Ductal Adenocarcinoma (PDAC)",[93,94,95,96,97],"Fibroblast Activation Protein Inhibitor","Positron Emission Tomography","Pancreatic ductal adenocarcinoma","PDAC","FAPI","2026-04-10",{"date":100,"type":101},"2026-04-15","ACTUAL",{"date":103,"type":101},"2025-12-02",{"date":105,"type":85},"2030-08-08",{"name":5,"class":6},1]